# Safety and Efficacy of IBI306 in HeFH Patients

> **NCT04179669** · PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 149 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** IBI306
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04179669
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-20
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179669, "Safety and Efficacy of IBI306 in HeFH Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04179669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*